Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Fartoux

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Gut|June 14, 2005
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis CL Fartoux, A Poujol-Robert, J Guéchot, et al.
Alimentary Pharmacology & Therapeutics|September 1, 2017
Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year periodR Pais, L Fartoux, C Goumard, et al.
Journal of Viral Hepatitis|March 31, 2015
Association between IL28B polymorphism, TNFα and biomarkers of insulin resistance in chronic hepatitis C-related insulin resistanceM Lemoine, S Chevaliez, J P Bastard, et al.
Nuklearmedizin. Nuclear Medicine|January 8, 2014
18F-fluorocholine may be taken-up by brown adipose tissueS Balogova, L Michaud, M Vereb, et al.
British Journal of Cancer|February 25, 2009
Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II studyT André, J M Reyes-Vidal, L Fartoux, et al.
British Journal of Cancer|March 23, 2018
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinomaD H Palmer, Y T Ma, M Peck-Radosavljevic, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Gut|June 14, 2005
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis CL Fartoux, A Poujol-Robert, J Guéchot, et al.
Alimentary Pharmacology & Therapeutics|September 1, 2017
Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year periodR Pais, L Fartoux, C Goumard, et al.
Journal of Viral Hepatitis|March 31, 2015
Association between IL28B polymorphism, TNFα and biomarkers of insulin resistance in chronic hepatitis C-related insulin resistanceM Lemoine, S Chevaliez, J P Bastard, et al.
Nuklearmedizin. Nuclear Medicine|January 8, 2014
18F-fluorocholine may be taken-up by brown adipose tissueS Balogova, L Michaud, M Vereb, et al.
British Journal of Cancer|February 25, 2009
Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II studyT André, J M Reyes-Vidal, L Fartoux, et al.
British Journal of Cancer|March 23, 2018
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinomaD H Palmer, Y T Ma, M Peck-Radosavljevic, et al.
Pageof 2